ClinicalTrials.gg

Program

Aminolevulinic Acid

Also written as “Aminolevulinic Acid (ALA)”, “5 Aminolevulinic Acid” and “PD P 506 A”.

Its studies are mostly in Keratosis, Actinic · Glioma · Glioblastoma · Breast Neoplasms · Malaria, led by 10 companies.

Furthest: phase 3, since May 7, 201422 company-led studies, 3 open or runningNext primary completion: Oct 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sun Pharmaceutical Industries100 open or runningphase 3since May 7, 2014Jun 24, 2008none ahead
Alpheus Medical21 open or runningphase 1since May 2, 2022May 2, 2022Oct 30, 2027phase 1 · NCT07862647
medac20 open or runningphase 3since Oct 18, 2005Oct 18, 2005none ahead
photonamic GmbH & Co. KG20 open or runningphase 2since Jul 11, 2018Jul 11, 2018none ahead
Hemerion Therapeutics11 open or runningphase 2since Feb 8, 2023Feb 8, 2023none ahead
Lee's Pharmaceutical11 open or runningphase 3since Nov 27, 2023Nov 27, 2023Dec 2027phase 3 · NCT06160492
Neopharma Japan10 open or runningphase 2since Jul 12, 2019Jul 12, 2019none ahead
Nobelpharma10 open or runningphase 3since Jul 16, 2010Jul 16, 2010none ahead
SBI ALApharma Canada10 open or runningphase 3since Mar 22, 2021Mar 22, 2021none ahead
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical10 open or runningphase 3since May 12, 2024May 12, 2024none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Oct 18, 2005.

  1. Oct 30, 2014Phase 2 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT02281136 · 29 enrolled · United States
  2. Jan 22, 2015Phase 2 study in Onychomycosismedac · NCT02355899 · 25 enrolled · Germany
  3. Dec 7, 20152 phase 2 studies in Keratosis, ActinicSun Pharmaceutical Industries · NCT02628236, NCT02632110
  4. Jan 13, 2017Phase 3 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT03024060 · United States
  5. Jul 11, 2018photonamic GmbH & Co. KG’s first study: phase 2 study in Keratosis, ActinicNew to photonamic GmbH & Co. KGphotonamic GmbH & Co. KG · NCT03606122 · 22 enrolled · Germany
  6. Mar 19, 2019Phase 2 study in Glioblastomaphotonamic GmbH & Co. KG · NCT03897491 · 17 enrolled · Germany
  7. Jul 12, 2019Neopharma Japan’s first study: phase 2 study in MalariaNew to Neopharma JapanNeopharma Japan · NCT04020653
  8. Mar 22, 2021SBI ALApharma Canada’s first study: phase 3 study in Breast NeoplasmsNew to SBI ALApharma CanadaSBI ALApharma Canada · NCT04815083 · 57 enrolled · United States
  9. May 2, 2022Alpheus Medical’s first study: phase 1 study in GliomaNew to Alpheus MedicalAlpheus Medical · NCT05362409 · 22 enrolled · United States
  10. Feb 8, 2023Hemerion Therapeutics’ first study: phase 2 study in GliomaNew to Hemerion TherapeuticsHemerion Therapeutics · NCT05736406 · 12 enrolled · United States, France
  11. Nov 27, 2023Lee's Pharmaceutical’s first study: phase 3 study in GliomaNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT06160492 · 79 planned · China
  12. May 12, 2024Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s first study: phase 3 study in 5-aminolevulinic AcidNew to Shanghai Fudan-Zhangjiang Bio-PharmaceuticalShanghai Fudan-Zhangjiang Bio-Pharmaceutical · NCT06417281 · 86 enrolled · China
  13. Sep 28, 2026Phase 1 study in GlioblastomaAlpheus Medical · NCT07862647 · 30 planned · United States
  14. Oct 27, 2026Primary completion moved from 2026-02 to 2027-12Date moved laterphase 3 · +22 months · NCT06160492

Ahead

  1. Oct 30, 2027Primary completion: phase 1 study in GlioblastomaAlpheus Medical · NCT07862647
  2. Dec 2027Primary completion: phase 3 study in GliomaLee's Pharmaceutical · NCT06160492

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07862647Glioblastoma · United States1RecruitingAlpheus MedicalOct 30, 202730
NCT064172815-aminolevulinic Acid · China3CompletedShanghai Fudan-Zhangjiang Bio-PharmaceuticalAug 19, 202586
NCT06160492Glioma · China3RecruitingLee's PharmaceuticalDec 202779
NCT05736406Glioma · United States, France2Active, not recruitingHemerion TherapeuticsMar 6, 202612
NCT05362409Glioma · United States1CompletedAlpheus MedicalDec 3, 202422
NCT04815083Breast Neoplasms · United States3TerminatedSBI ALApharma CanadaOct 22, 202457
NCT04020653Malaria2WithdrawnNeopharma JapanMay 31, 20200
NCT03897491Glioblastoma · Germany2Terminatedphotonamic GmbH & Co. KGApr 8, 202617
NCT03606122Keratosis, Actinic · Germany2Completedphotonamic GmbH & Co. KGJul 16, 201922
NCT03024060Keratosis, Actinic · United States3WithdrawnSun Pharmaceutical IndustriesSep 20170
NCT02632110Keratosis, Actinic · United States2CompletedSun Pharmaceutical IndustriesSep 12, 2016137
NCT02628236Keratosis, Actinic · United States2CompletedSun Pharmaceutical IndustriesMay 201614
NCT02355899Onychomycosis · Germany2CompletedmedacAug 23, 201725
NCT02281136Keratosis, Actinic · United States2CompletedSun Pharmaceutical IndustriesApr 201529
NCT02239679Keratosis, Actinic · United States2CompletedSun Pharmaceutical IndustriesJul 2016166
NCT02137785Keratosis, Actinic · United States3CompletedSun Pharmaceutical IndustriesMar 2015269
NCT01475955Keratosis, Actinic · United States2CompletedSun Pharmaceutical IndustriesNov 2012235
NCT01458587Keratosis, Actinic · United States2CompletedSun Pharmaceutical IndustriesJul 201270
NCT01167322Glioma · Japan3CompletedNobelpharmaDec 201145
NCT00865878Keratosis, Actinic · United States2TerminatedSun Pharmaceutical IndustriesSep 20116
NCT00706433Acne Vulgaris · United States2CompletedSun Pharmaceutical IndustriesJul 2008266
NCT00241670Brain Neoplasms3CompletedmedacJul 2004415

How it is read

Names in the registry

  • “Aminolevulinic Acid (ALA)”, 3 entries
  • “5 Aminolevulinic Acid”, 2 entries
  • “PD P 506 A”, 2 entries
  • “Aminolevulinic Acid”, 2 entries
  • “ALA”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.